A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
Summary
To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.
Timeline
- Start
- 2013-12
- Primary completion
- 2015-12
- Completion
- 2016-09
Outcome
Met primary endpoint
release “Phase 2 clinical trial in which SGX942 (dusquetide) demonstrated a statistically significant reduction in the median duration of severe oral mucositis” soligenix.com ↗
release “In this clinical trial that enrolled 111 patients, SGX942 (1.5 mg/kg dusquetide) demonstrated a positive, clinically meaningful reduction in the median duration” soligenix.com ↗
release “Soligenix has reported positive Phase 2 results with SGX942 in the treatment of oral mucositis in head and neck cancer (HNC) patients.” soligenix.com ↗
release “SGX942 at a dose of 1.5 mg/kg successfully reduced the median duration of severe oral mucositis by 50% in all patients” soligenix.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dusquetide | Protein / enzyme biologic | 1.5 mg/kg | — |
| Subject | Dusquetide | Protein / enzyme biologic | 3 mg/kg | — |
| Subject | Dusquetide | Protein / enzyme biologic | 6 mg/kg | — |